FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Clinical Trials
Topic : Progress in the treatment of triple-negative breast cancer
Most relevant for: People with triple-negative breast cancer
During the December 2023 San Antonio Breast Cancer Symposium, Dr. Melinda Telli presented a summary of research that has led to better treatments for triple-negative breast cancer (TNBC). These treatments now include drugs called targeted therapies and immunotherapies for both early and late stages of TNBC. (Posted 3/19/24)
Read MoreUpdate : A breast cancer vaccine for people with an inherited BRCA1, BRCA2 or PALB2 mutation
Most relevant for: People at increased risk for breast cancer undergoing prophylactic bilateral mastectomy due to an inherited mutation in BRCA1, BRCA2 or PALB2. People with TNBC who still have breast cancer after chemotherapy.
A breast cancer vaccine is showing promise in early clinical trials. Initially, the vaccine was tested in people with triple-negative breast cancer (TNBC) who were at high risk for recurrence. Now the vaccine is being tested to lower breast cancer risk among people with an inherited mutation in BRCA1, BRCA2 or PALB2. It is also being tested in people with triple-negative breast cancer who are at high risk for recurrence and are taking the immunotherapy drug Keytruda (pembrolizumab) after completing chemotherapy. (Posted 1/31/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
View Related Clinical TrialsArticle : Promising drug for cancer treatment begins clinical trials
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
View Related Clinical TrialsMost relevant for: People with solid tumors.
Researchers at City of Hope are testing a new type of cancer treatment drug. When tested in animals and cells taken from human cancers, this new drug prevented the growth of many types of cancer. Initial clinical trials in people have just started. (Posted 9/7/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Personalized vaccines may help pancreatic cancer treatment
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with pancreatic cancer who have tumors that can be removed by surgery
Pancreatic cancer is usually diagnosed at a late stage when patients have few treatment options. Early study results showed that a pancreatic cancer vaccine delayed the return of cancer for nearly half of the participants. (Posted 8/29/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : New treatment option for advanced or recurrent endometrial cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with advanced or recurrent endometrial cancer
If you have advanced or recurrent endometrial cancer, there is a new treatment called Jemperli (dostarlimab) that could be an option for you. This study looked at how well Jemperli worked compared to standard treatment. Based on these results, the Food and Drug Administration (FDA) approved the combination of Jemperli and chemotherapy for certain types of advanced endometrial cancer. (Posted 8/4/23)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with HR-positive HER2-negative advanced breast cancer
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : New oral drug treatment for some advanced breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with HR-positive, HER2-negative advanced breast cancer
The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Promising early results for treating metastatic prostate cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Read MoreUpdate : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations
Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy
A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for people with DNA mismatch repair deficient rectal cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with rectal cancer with high mutational burden or mismatch repair problems including people with Lynch syndrome.
A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22) Este artículo está disponible en español.
Read More